Previous 10 | Next 10 |
Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financial position with $465.4 million as of August 31, 2021 SAN FRANCISCO, Oct. 14, 2021 (GLOBE N...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
Zerbor/iStock via Getty Images Nurix Therapeutics ([[NRIX]] -2.9%) swung to a Q2 2021 loss of $26.4 million (-$0.60 per share) from net income of $7.6M ($0.00 per share) in the prior-year period, hampered by rising R&D, and general and administrative expenses. Nurix's Q2 ended on May 31. ...
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in 2021 Strong financial position with $496 million as of May 31, 2021 ...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Nurix Therapeutics (NRIX) announces that Stefani A. Wolff has joined the company as chief operating officer and executive VP of product development. Ms. Wolff brings over 30 years of leadership experience in oncology and immunology most recently from Principia Biophar...
SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of...
APTO is presenting new data at EHA21 for its Btk inhibitor, Luxeptinib. The data could be a catalyst event (up or down) for this stock. There's a lot of competition for non-covalent Btk inhibitors in blood cancers. For further details see: Aptose: Cancer Trial Catalyst A...
Organon attracts neutral views on the first day of tradingMerck (MRK) spinoff focused on women’s health and biosimilars, Organon (OGN), staged a late-afternoon rally to end ~8.4% higher yesterday on its first day of trading as a separate entity.In contrast to two buy ratings it pr...
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) ...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...